5 reasons this might be a long battle (I hope for the sufferers you are right).
1- Even the best drugs are subject to viral mutation if they aren't administered properly.
2-Poor countries like North Korea, Myanmar, Bangladesh, etc. will remain pools of HCV infection in the region.
3-Policies for diagnosis and screening are weak even in developed countries like the U.S. Too many people don't know they are infected until their liver starts to fail.
4-Certain poor countries may not find it cost effective to use best in class drugs for treatment.
5-Tela/Boceprevir haven't proven their resistance profile in the real world setting. Will they be susceptible to mutation?
Market Data 
Markets 
AI
